Article Text

Download PDFPDF
Featured correspondence
What is the best dose of aspirin in association with P2Y12 antagonists?
  1. Marco Cattaneo
  1. Medicina 3, Ospedale San Paolo, Università degli Studi di Milano, Milan, Italy
  1. Correspondence to Dr Marco Cattaneo, Medicina 3, Ospedale San Paolo. Università degli Studi di Milano. Via di RudinÌ 8, Milano 20142, Italy; marco.cattaneo{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the Editor In their Viewpoint article, Warner et al1 hypothesised that the administration of aspirin to patients who are treated with potent antagonists of the platelet P2Y12 receptors might increase cardiovascular risk. The authors' hypothesis is based on the observation that P2Y12 antagonists inhibit the platelet production of thromboxane A2 (TxA2) (which would render the use of aspirin superfluous), and on the consideration that aspirin may cause adverse effects. It is my opinion that there is no evidence yet to suggest …

View Full Text


  • Linked articles 216820.

  • Competing interests Marco Cattaneo participated to advisory board meetings and received lecture honoraria by AstraZeneca, Eli Lilli-Daiichi Sankyo.

  • Provenance and peer review Not commissioned; not externally peer reviewed.

Linked Articles

  • PostScript
    Timothy D Warner